We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

PHASE Scientific Launches RNA Extraction Kit for COVID-19 Test

By LabMedica International staff writers
Posted on 10 Apr 2020
Print article
Image: PHASIFY VIRAL RNA Extraction Kit (Photo courtesy of PHASE Scientific)
Image: PHASIFY VIRAL RNA Extraction Kit (Photo courtesy of PHASE Scientific)
PHASE Scientific (Hong Kong) has commercially launched the PHASIFY VIRAL RNA Extraction Kit as part of its global effort to help detect and control the COVID-19 disease. PHASIFY VIRAL purifies and concentrates viral RNA in patient viral transport media samples. This novel technology outperforms conventional solid phase extraction methods in RNA yield and concentration.

PHASE Scientific is a biotech company which builds tools that empower people by giving them better information about their health. The PHASIFY VIRAL kit, which incorporates the PHASIFY proprietary liquid phase extraction technology, produces greater viral RNA yields. This is enabled by an increased sample input volume up to 1 mL per extraction, and enhanced final viral RNA concentration with flexible elution volume down to 10 µL. The kit’s easy-to-use design requires no additional specialized equipment, such as magnetic racks and vacuum pumps, for operation.

PHASIFY concentrates target molecules by 10-100x, making them easier to detect. PHASIFY can make any diagnostic test more affordable, faster, easier, and more accurate. As proven by validation data, the PHASIFY VIRAL RNA extraction kit enables a 3-6 cycle threshold reduction compared to solid phase extraction. The applications of the PHASIFY VIRAL RNA Extraction Kit can be expanded to cover a wide scope of RNA-type virus extractions to help research institutes, hospitals, and diagnostic labs to improve diagnostic performance.

“We believe the PHASIFY VIRAL kit will be a new breakthrough approach for the fight against the COVID-19 disease. Our products can help increase detection sensitivity, decrease false negative results, enable earlier detection and increase confidence in diagnostic test results,” said Ricky Chiu, Ph.D., Founder and CEO of PHASE Scientific.

Related Links:
PHASE Scientific

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
SARS-CoV-2 Test
One Step SARS-CoV-2 Nucleic Acid Detection Kit (P761H)

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A massive study has identified new biomarkers for renal cancer subtypes, improving diagnosis and treatment (Photo courtesy of Jessica Johnson)

Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes

Renal cell carcinomas (RCCs) are notably diverse, encompassing over 20 distinct subtypes and generally categorized into clear cell and non-clear cell types; around 20% of all RCCs fall into the non-clear... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more